Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Aug;190(3):318-327.
doi: 10.1111/bjh.16506. Epub 2020 Feb 14.

Prospects for achieving treatment-free remission in chronic myeloid leukaemia

Giuseppe Saglio  1 , Robert P Gale  2
Affiliations
Review

Prospects for achieving treatment-free remission in chronic myeloid leukaemia

Giuseppe Saglio et al. Br J Haematol. 2020 Aug.

Abstract

In addition to the best possible overall survival, discontinuation of the tyrosine kinase-inhibitor (TKI) treatment [treatment free remission (TFR)] without observing a recurrence of the disease has become a major goal of the therapy of chronic myelogenous leukemia (CML). Many clinical studies have demonstrated that TFR is possible, although for the moment limited to a fraction of the CML patients able to achieve a stable deep molecular response (DMR). The factors associated to the possibility of remaining in TFR or of losing it, have been investigated by a number of controlled and observation clinical trials and although total TKI treatment duration, DMR duration and stability and, more recently, also the depth of the molecular response obtained at the time of discontinuation have been shown to be significant elements, most of the factors associated with a higher possibility of a successful discontinuation still remain elusive and are here reviewed.

Keywords: CML; treatment-free remission; tyrosine kinase inhibitors.

PubMed Disclaimer

References

    1. Barrett, A.J. (2008) Understanding and harnessing the graft‐versus‐leukaemia effect. British Journal of Haematology, 142, 877–88. - PubMed
    1. Bernardi, S. , Malagola, M. , Zanaglio, C. , Polverelli, N. , Dereli Eke, E. , D’Adda, M. , Farina, M. , Bucelli, C. , Scaffidi, L. , Toffoletti, E. , Deambrogi, C. , Stagno, F. , Bergamaschi, M. , Franceschini, L. , Abruzzese, E. , Divona, M.D. , Gobbi, M. , Di Raimondo, F. , Gaidano, G. , Tiribelli, M. , Bonifacio, M. , Cattaneo, C. , Iurlo, A. & Russo, D. (2019) Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation. Cancer Medicine, 8, 2041–2055. - PMC - PubMed
    1. Branford, S. , Wang, P. , Yeung, D.T. , Thomson, D. , Purins, A. , Wadham, C. , Shahrin, N.H. , Marum, J.E. , Nataren, N. , Parker, W.T. , Geoghegan, J. , Feng, J. , Shanmuganathan, N. , Mueller, M.C. , Dietz, C. , Stangl, D. , Donaldson, Z. , Altamura, H. , Georgievski, J. , Braley, J. , Brown, A. , Hahn, C. , Walker, I. , Kim, S.H. , Choi, S.Y. , Park, S.H. , Kim, D.W. , White, D.L. , Yong, A.S.M. , Ross, D.M. , Scott, H.S. , Schreiber, A.W. & Hughes, T.P. (2018) Integrative genomic analysis reveals cancer‐associated mutations at diagnosis of CML in patients with high‐risk disease. Blood, 132, 948–961. - PubMed
    1. Branford, S. , Kim, D.D.H. , Apperley, J.F. , Eide, C.A. , Mustjoki, S. , Ong, S.T. , Nteliopoulos, G. , Ernst, T. , Chuah, C. , Gambacorti‐Passerini, C. , Mauro, M.J. , Druker, B.J. , Kim, D.W. , Mahon, F.X. , Cortes, J. , Radich, J.P. , Hochhaus, A. , Hughes, T.P. & Alliance, I.C.F.G. (2019) Laying the foundation for genomically‐based risk assessment in chronic myeloid leukemia. Leukemia, 33, 1835–1850. - PMC - PubMed
    1. Breccia, M. & Foà, R. (2018) Current Information and Recommendations on the Discontinuation of TKI Inhibitors in Chronic Myeloid Leukemia. Curr Oncol Rep, 20, 23. - PubMed

Publication types

MeSH terms

Substances